Karyopharm Therapeutics IncKaryopharm Therapeutics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

This webpage includes a Q&A table on Karyopharm Therapeutics Inc. Jump to the end of this page for potential risks for Karyopharm Therapeutics Inc based on industry, location and marketcap. Other companies in the rating industry group for Karyopharm Therapeutics Inc are displayed below.

Karyopharm Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 7.6; made up of an environmental score of 6.4, social score of 8.0 and governance score of 8.0.

SDG Transparency Score for Karyopharm Therapeutics Inc 
Low
0 - 3
Medium
4 - 6

7.6

High Impact
7 - 10
Last Score Update: 2023-07-01
What drives the score for Karyopharm Therapeutics Inc 
6.4

Environmental

8.0

Social

8.0

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Novartis AG
9.2
High
2Daiichi Sankyo Co Ltd
8.9
High
187Richter Gedeon Vegyeszeti Gyar Nyrt
7.7
High
187Vitrolife AB
7.7
High
209Karyopharm Therapeutics Inc
7.6
High
209Actinogen Medical Ltd
7.6
High
209Bajaj Healthcare Ltd
7.6
High
.........
2749Xynomic Pharmaceuticals Holdings Inc
0.0
Low
2749Zyden Gentec Ltd
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Karyopharm Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc offer flexible work?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose water use targets?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Karyopharm Therapeutics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Karyopharm Therapeutics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Karyopharm Therapeutics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Karyopharm Therapeutics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Karyopharm Therapeutics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Karyopharm Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Sorry!

Failed to process!